Doyen et al. FIND-RA study. RA for >1<10 years. RA-ILD 12%, air trapping 58%, rheumatoid nodules 11%. @RheumNow #ACR22 Abstr#1393 https://t.co/Sy1qwZJq5E https://t.co/ww8HgHT32E

• Lung Involvement in Early Rheumatoid Arthritis, Interim Analysis of the FINDRA …

Aim for drug free remission in early RA? After 1 yr remission Pts randomized to stop Rx vs 1/2 dose. More flares if no Rx. For 1/2 dose if 2 yrs remission randomize to stop or stay at 1/2 dose. 2X more flares if d/c Rx. Abst2013 Arctic rewind #ACR22 @rheumnow #ACRBest Relevant ? https://t.co/nfQPExhbYj

Plenary: Real-world observational study >1500 pts with IA, 1 year retention infliximab biosimilar CT-P13 to GP1111 switch was high. Retention was higher in originator-experienced (92vs83%) & low disease activity Nabi H, DANBIO Abs1112 https://t.co/z84AMUS3GK #ACR22 @RheumNow https://t.co/SgGhd33Esl

• Biosimilar-to-Biosimilar Switching in Routine Care – Results on &gt;1,600 Patie…

Does MTX dose matter for COVID mRNA vaccine immunogenicity in RA pts? Single-center (n=126) with one MTX dose WH post-each vaccine Similar humoral response Big error bars suggest other factors more important ABST0913 #ACR22 @RheumNow (not pretty graphs but data interesting!) https://t.co/FFfTWiNjUY

Data from CorEvitas RA registry shows persistence for first-line monotherapy with etanercept, adalimumab and JAKis no different at 12 months. 20-25% switching at 12-months. Clearly more to secondary failure than anti-drug antibodies. @RheumNow #ACR22 https://t.co/FeP0UAykUg https://t.co/ad9w9lI0Hu

• Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etan…

Raadsen et al. RA-specific CV risk specifically targets pre-existing atherosclerotic vessels. So if no baseline CVD, traditional risk factors are main driver rather than RA. Risk without prevalent CVD (HR 1.16 95%CI 0.88 –1.53) @RheumNow #ACR22 Abstr#1408 https://t.co/1Y6WeEFmim https://t.co/qG3RMNnbqt

• In RA Patients Without Prevalent CVD, Incident CVD Is Only Associated with Trad…

Johnson et al. Increased risk of heart failure and heart failure mortality in RA. No improvement over time. @RheumNow #ACR22 Abstr#1204 https://t.co/MGEgmORGuL https://t.co/9zDYjZiCh1

• An Increased Risk of Heart Failure and Heart Failure-Related Death Persists in …

Pala et al. Increasing disease activity by CDAI associated increasing patient-reported cognitive dysfunction in RA. More pronounced in younger patients. @RheumNow #ACR22 Abstr#1397 https://t.co/eRFxe27qgq https://t.co/NUtTaAcrik

• The Impact of Disease Activity on Patient-Reported Cognitive Dysfunction in Rhe…

Meng et al. ESR/CRP and steroid associated increased risk of MACE in IA. NSAIDs/COX-2 and MTX associated reduced risk of MACE in IA. @RheumNow #ACR22 Abstr#1207 https://t.co/OvjNZkpWpy https://t.co/9NMIJPcV9G

• Risk Factors for Major Cardiovascular Events (MACE) in Inflammatory Arthritis: …